SRPT
Sarepta Therapeutics, Inc. [SRPT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SRPT Stock Summary
Top 10 Correlated Stocks
SRPT
In the News
Frank Sands' Top 1st-Quarter Buys
Sands Capital Management recently disclosed its 13F portfolio updates for the first quarter of 2023, which ended on March 31.
Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
The FDA has delayed its decision on Sarepta's gene therapy, SRP-9001, and investors are concerned. An approval could still be coming, but it may be narrower in scope.
Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
Sarepta focuses on gene therapies to treat rare diseases. SRP-9001 is designed to correct the genetic mutation that can cause Duchenne muscular dystrophy.
Sarepta Therapeutics shares fall as FDA delays decision on gene therapy
Sarepta Therapeutics shares fell by more than 12% on the news the US Food and Drug Administration (FDA) requires more time for its review of the company's Biologics License Application (BLA) of its investigational gene therapy SRP-9001 for Duchenne muscular dystrophy. The company said the FDA requires additional time to complete the review, including final label negotiations and postmarketing commitment discussions, and it expects to complete the review by June 22, 2023, almost a month later than its previous regulatory action date of May 29.
Biotech Stock Drops on FDA Update
Sarepta Therapeutics Inc (NASDAQ:SRPT) is gaining some attention in the biotech realm today.
2 Under-the-Radar Biotech Stocks to Buy in 2023
Exelixis and Sarepta are relatively small players in the highly competitive biotech industry. Both drugmakers have found success by focusing most of their efforts on niche areas.
Sarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy.
Investors on Wednesday seemed to take the delay as a sign that opponents of approval within the agency were winning out.
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy
The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble. The post Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene Therapy appeared first on Investor's Business Daily.
SRPT Financial details
SRPT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.54 | 5.17 | 6.93 | 8.64 | 11.48 | |
| Net income per share | -5.46 | -9.71 | -7.11 | -5.15 | -8.66 | |
| Operating cash flow per share | -5.87 | -6.2 | 1.38 | -5.45 | -4 | |
| Free cash flow per share | -6.84 | -7.05 | 0.32 | -5.93 | -4.38 | |
| Cash per share | 17.72 | 15.28 | 24.87 | 26.04 | 24.48 | |
| Book value per share | 15.58 | 11.11 | 9.77 | 11.42 | 4.74 | |
| Tangible book value per share | 15.41 | 10.94 | 9.6 | 11.24 | 4.64 | |
| Share holders equity per share | 15.58 | 11.11 | 9.77 | 11.42 | 4.74 | |
| Interest debt per share | 6.86 | 10.33 | 14.53 | 14.79 | 20.56 | |
| Market cap | 7.23B | 9.5B | 13.29B | 7.32B | 10.53B | |
| Enterprise value | 8.08B | 9.39B | 12.86B | 6.34B | 11.18B | |
| P/E ratio | -19.98 | -13.28 | -23.98 | -17.47 | -14.97 | |
| Price to sales ratio | 24.02 | 24.94 | 24.61 | 10.43 | 11.29 | |
| POCF ratio | -18.6 | -20.81 | 123.67 | -16.51 | -32.37 | |
| PFCF ratio | -15.96 | -18.3 | 526.07 | -15.19 | -29.56 | |
| P/B Ratio | 7 | 11.61 | 17.45 | 7.89 | 27.35 | |
| PTB ratio | 7 | 11.61 | 17.45 | 7.89 | 27.35 | |
| EV to sales | 26.85 | 24.67 | 23.81 | 9.03 | 11.98 | |
| Enterprise value over EBITDA | -25.53 | -20.01 | -24.3 | -15.38 | -23.61 | |
| EV to operating cash flow | -20.8 | -20.58 | 119.67 | -14.31 | -34.36 | |
| EV to free cash flow | -17.84 | -18.09 | 509.06 | -13.16 | -31.39 | |
| Earnings yield | -0.05 | -0.08 | -0.04 | -0.06 | -0.07 | |
| Free cash flow yield | -0.06 | -0.05 | 0 | -0.07 | -0.03 | |
| Debt to equity | 0.59 | 1.23 | 2.92 | 2.39 | 7.13 | |
| Debt to assets | 0.37 | 0.55 | 0.74 | 0.71 | 0.88 | |
| Net debt to EBITDA | -2.69 | 0.22 | 0.81 | 2.37 | -1.37 | |
| Current ratio | 8.21 | 5.55 | 5.97 | 5.75 | 4.13 | |
| Interest coverage | -10.19 | -17.03 | -9.41 | -7.08 | -10.07 | |
| Income quality | 1.07 | 0.64 | -0.19 | 1.06 | 0.46 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.7 | 0.75 | 0.59 | 0.4 | 0.48 | |
| Research and developement to revenue | 1.33 | 1.47 | 1.34 | 1.1 | 0.94 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.17 | 0.14 | -0.76 | 0.09 | 0.09 | |
| Capex to revenue | -0.21 | -0.16 | -0.15 | -0.05 | -0.03 | |
| Capex to depreciation | -5.25 | -2.05 | -3.05 | -1.01 | -0.74 | |
| Stock based compensation to revenue | 0.17 | 0.21 | 0.2 | 0.16 | 0.25 | |
| Graham number | 43.76 | 49.29 | 39.53 | 36.39 | 30.38 | |
| ROIC | -0.4 | -6.19 | 4.29 | 0.39 | -0.5 | |
| Return on tangible assets | -0.22 | -0.39 | -0.19 | -0.13 | -0.23 | |
| Graham Net | 10.02 | 3.75 | -0.83 | 1.45 | -5.63 | |
| Working capital | 1.25B | 1.2B | 2.07B | 2.15B | 1.94B | |
| Tangible asset value | 1.02B | 805.69M | 748.13M | 913.77M | 377.37M | |
| Net current asset value | 816.38M | 464.28M | 262.24M | 384.13M | -185.56M | |
| Invested capital | 0.41 | 0.89 | 1.41 | 1.23 | 4.2 | |
| Average receivables | 39.26M | 71.49M | 116.26M | 155.11M | 215.67M | |
| Average payables | 21.15M | 50.96M | 89.59M | 93.92M | 86.31M | |
| Average inventory | 104.53M | 148.41M | 201.67M | 209.09M | 195.09M | |
| Days sales outstanding | 59.47 | 90.03 | 93.65 | 89.26 | 101.59 | |
| Days payables outstanding | 361.11 | 439.23 | 639.74 | 288.62 | 249.98 | |
| Days of inventory on hand | 1.34K | 1.11K | 1.34K | 700.34 | 531.82 | |
| Receivables turnover | 6.14 | 4.05 | 3.9 | 4.09 | 3.59 | |
| Payables turnover | 1.01 | 0.83 | 0.57 | 1.26 | 1.46 | |
| Inventory turnover | 0.27 | 0.33 | 0.27 | 0.52 | 0.69 | |
| ROE | -0.35 | -0.87 | -0.73 | -0.45 | -1.83 | |
| Capex per share | -0.97 | -0.85 | -1.05 | -0.47 | -0.38 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.42 | 2.67 | 2.63 | 3.18 | 2.87 | |
| Net income per share | -1.2 | -2.65 | -2.94 | -1.34 | -5.86 | |
| Operating cash flow per share | -1.16 | -0.76 | -0.74 | -1.14 | -2.37 | |
| Free cash flow per share | -1.22 | -0.87 | -0.84 | -1.23 | -2.48 | |
| Cash per share | 23.08 | 22.03 | 23.65 | 24.48 | 21.34 | |
| Book value per share | 9.82 | 8.3 | 4.92 | 4.74 | 8.08 | |
| Tangible book value per share | 9.82 | 8.15 | 4.77 | 4.64 | 8.08 | |
| Share holders equity per share | 9.82 | 8.3 | 4.92 | 4.74 | 8.08 | |
| Interest debt per share | 13.22 | 13.21 | 18.18 | 19.99 | 14.68 | |
| Market cap | 6.82B | 6.56B | 9.69B | 10.53B | 12.15B | |
| Enterprise value | 6.72B | 6.83B | 10.23B | 11.18B | 12.57B | |
| P/E ratio | -16.23 | -7.08 | -9.4 | -24.1 | -5.88 | |
| Price to sales ratio | 32.33 | 28.1 | 42.07 | 40.75 | 47.95 | |
| POCF ratio | -67.37 | -98.18 | -149.1 | -113.97 | -58.05 | |
| PFCF ratio | -63.87 | -86.44 | -132.34 | -104.93 | -55.53 | |
| P/B Ratio | 7.95 | 9.03 | 22.48 | 27.35 | 17.05 | |
| PTB ratio | 7.95 | 9.03 | 22.48 | 27.35 | 17.05 | |
| EV to sales | 31.87 | 29.26 | 44.41 | 43.26 | 49.59 | |
| Enterprise value over EBITDA | -86.56 | -33.79 | -91.11 | -137.2 | -116.67 | |
| EV to operating cash flow | -66.42 | -102.25 | -157.41 | -121.01 | -60.04 | |
| EV to free cash flow | -62.96 | -90.01 | -139.71 | -111.41 | -57.43 | |
| Earnings yield | -0.02 | -0.04 | -0.03 | -0.01 | -0.04 | |
| Free cash flow yield | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Debt to equity | 2.57 | 3.13 | 6.33 | 7.13 | 3.29 | |
| Debt to assets | 0.72 | 0.76 | 0.86 | 0.88 | 0.77 | |
| Net debt to EBITDA | 1.24 | -1.34 | -4.81 | -7.98 | -3.87 | |
| Current ratio | 5.56 | 4.53 | 4.36 | 4.13 | 4.63 | |
| Interest coverage | -5.5 | -13.17 | -8.91 | -15.97 | -21.84 | |
| Income quality | 0.96 | 0.29 | 0.25 | 0.85 | 0.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.34 | 0.66 | 0.46 | 0.47 | 0.44 | |
| Research and developement to revenue | 0.92 | 1.08 | 0.94 | 0.83 | 0.97 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.05 | 0.14 | 0.13 | 0.09 | 0.05 | |
| Capex to revenue | -0.03 | -0.04 | -0.04 | -0.03 | -0.04 | |
| Capex to depreciation | -0.52 | -0.92 | -0.77 | -0.75 | -0.84 | |
| Stock based compensation to revenue | 0.14 | 0.44 | 0.22 | 0.2 | 0.16 | |
| Graham number | 16.31 | 22.23 | 18.04 | 11.97 | 32.64 | |
| ROIC | -0.16 | -0.18 | -0.14 | -0.1 | -0.12 | |
| Return on tangible assets | -0.03 | -0.08 | -0.08 | -0.04 | -0.17 | |
| Graham Net | 0.71 | -0.75 | -4.28 | -5.63 | -1.67 | |
| Working capital | 2.08B | 1.92B | 2.02B | 1.94B | 1.95B | |
| Tangible asset value | 843.56M | 713.4M | 417.78M | 377.37M | 705.55M | |
| Net current asset value | 331.68M | 198.9M | -99.38M | -185.56M | 141.34M | |
| Invested capital | 1.33 | 1.57 | 3.66 | 4.2 | 1.81 | |
| Average receivables | 184.42M | 213.74M | 226.86M | 241.57M | 273.89M | |
| Average payables | 65.37M | 55.11M | 87.33M | 107.17M | 101.29M | |
| Average inventory | 192.6M | 203.55M | 214.64M | 212.58M | 203.32M | |
| Days sales outstanding | 84.18 | 88.76 | 87.33 | 90.44 | 102.28 | |
| Days payables outstanding | 154.59 | 133.84 | 266.86 | 280.16 | 274.26 | |
| Days of inventory on hand | 569.59 | 495.53 | 498.28 | 596.03 | 520.91 | |
| Receivables turnover | 1.07 | 1.01 | 1.03 | 1 | 0.88 | |
| Payables turnover | 0.58 | 0.67 | 0.34 | 0.32 | 0.33 | |
| Inventory turnover | 0.16 | 0.18 | 0.18 | 0.15 | 0.17 | |
| ROE | -0.12 | -0.32 | -0.6 | -0.28 | -0.73 | |
| Capex per share | -0.06 | -0.1 | -0.09 | -0.1 | -0.11 |
SRPT Frequently Asked Questions
What is Sarepta Therapeutics, Inc. stock symbol ?
Sarepta Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol SRPT
Is Sarepta Therapeutics, Inc. buy or a sell ?
18 stock analysts have 18 predictions with a medium analyst target price of $137.11. The lowest prediction is $80 and the highest is $187
What is SRPT stock prediction ?
What is Sarepta Therapeutics, Inc. stock quote today ?
Sarepta Therapeutics, Inc. stock price is $127.04 today.
Is Sarepta Therapeutics, Inc. stock public?
Yes, Sarepta Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.7M
- Market Capitalization 11.66B
- Employee 1.16K
- CEO Mr. Douglas S. Ingram Esq.
- Headquarters Cambridge,MA,US
- IPO Date 1997-06-04
-
Website
https://www.sarepta.com 
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
